ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / BNR / options
KEQU (69) SERA (30) XGN (36) TLSI (31) ⌘ Pro Terminal β†’

Burning Rock Biotech Limited (BNR) Options Positioning, Max Pain & Unusual Sweeps

$10.90 -1.36% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.85

Burning Rock Biotech Limited (BNR) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (20/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE E β€’ RED ALERT Cap $116.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNR Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BNR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Burning Rock Biotech Limited (NASDAQ: BNR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $10.90 (-1.36% 1D, market cap $116.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNR ranks #992 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BNR compare to KEQU and SERA in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), BNR carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 74.7%, and ROIC of -35.0%. By comparison, KEQU (Kewaunee Scientific Corporation) holds a C+ grade (69/100 RQD, P/E 10.1x, ROIC 16.7%, cap $97.0M) and SERA (Sera Prognostics Inc. (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $81.3M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNR?
β–Ό

Per BNR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001792267), Burning Rock Biotech Limited generated $77.2M in revenue (+9.2% YoY), -$7.9M in net income, and -$4.8M in free cash flow against $117.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.85 (-0.43%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (20/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510020
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk E
Cash (3)Whales (3)SEC (8)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.1% Base Target
$44 Bull$9 Base$7 Bear
πŸ“¬ FREE BNR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BNR)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (20/100 Composite)
πŸ” WHY BNR SCORES 20/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (40% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Cash Engine Quality+4/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 74.7% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
28
Grade E$15.00-18.1% Next Q
Q2 (-2Q)
25
Grade E$12.29-9.3% Next Q
Q3 (-1Q)
23
Grade E$11.15-2.2% Next Q
Current
20
Grade E$10.90-11.8% Hist 90D Ξ±
Trajectory: E (28) β†’ E (20)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BNR Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BNR currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.27) and Max Pain ($11.45) forces dealer call-delta covering toward $43.81.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNRβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBNR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 20%NO 80%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BNR)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BNR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNR)

  • βœ“Walkthrough of BNR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BNR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.59%β–Ό SUPPORT BREAKDOWN
2026-11-02O $12.26H $12.26L $10.90C $10.90VOL 29.8K
RES: $22.66SUP: $13.05SMA50: $13.27SMA200: $16.27
$20.81$17.01$13.21$9.41$5.61RES $22.66SUP $13.05$10.902026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BNR Butterfly Map β†’ + Track BNR β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +9.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BNR today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BNR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BNR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNR)

Health Care Rank #992 of 1016 βš”οΈ KEQU vs BNR Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BNR vs. KEQU, SERA, XGN, TLSI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Burning Rock Biotech Limited (BNR) ranks #992 by composite RQD confidence (20/100, grade E) and #639 by equity capitalization ($116.5M). Within this direct 5-issuer industry benchmark cohort, KEQU leads on earnings valuation at 10.1x trailing P/E, while KEQU leads on capital efficiency and profitability with 16.7% ROIC and 28.5% gross margin. KEQU currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with BNR at 20/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BNR ACTIVE
Burning Rock Biotech Limited
E 20/100 β€” 74.7% -35.0% -1.36% $116.5M Benchmark Subject
KEQU
Kewaunee Scientific Corporation
C+ 69/100 10.1x 28.5% 16.7% -0.21% $97.0M /kequ-vs-bnr β†’
SERA
Sera Prognostics Inc. (Class A)
E 30/100 β€” -30.0% -35.0% -0.97% $81.3M /sera-vs-bnr β†’
XGN
Exagen Inc.
D- 36/100 β€” 58.3% -35.0% -1.26% $210.8M /xgn-vs-bnr β†’
TLSI
TriSalus Life Sciences Inc.
E 31/100 β€” 84.6% -35.0% -4.14% $237.7M /tlsi-vs-bnr β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001792267

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Burning Rock Biotech Limited (BNR) reported GAAP revenue of $77.2M (+9.2% vs. FY2024 revenue of $70.7M , and +1.9% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of -$4.1M, and free cash flow of -$4.8M (+64.0% YoY). On the balance sheet, BNR closed FY2025 with $117.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $77.2M -$7.9M -$4.1M -$4.8M $117.3M β€”
FY2024 (FY) 2024-12-31 $70.7M -$47.5M -$12.6M -$13.4M $121.3M β€”
FY2023 (FY) 2023-12-31 $75.7M -$92.1M -$36.0M -$36.0M β€” β€”

3. BNR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Burning Rock Biotech Limited (NASDAQ: BNR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $10.90 (-1.36% 1D, market cap $116.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNR ranks #992 in composite RQD confidence.

How does BNR compare to KEQU and SERA in the Health Care sector?

Within the Health Care sector (Medical Specialities), BNR carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 74.7%, and ROIC of -35.0%. By comparison, KEQU (Kewaunee Scientific Corporation) holds a C+ grade (69/100 RQD, P/E 10.1x, ROIC 16.7%, cap $97.0M) and SERA (Sera Prognostics Inc. (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $81.3M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BNR?

Per BNR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001792267), Burning Rock Biotech Limited generated $77.2M in revenue (+9.2% YoY), -$7.9M in net income, and -$4.8M in free cash flow against $117.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BNR trading relative to its 50-day, 200-day, and 52-week technical levels?

BNR last traded at $10.90 (-1.36% on volume of 12,166 shares), positioning the stock -17.86% below its 50-day simple moving average ($13.27) and -33.01% below its 200-day simple moving average ($16.27). Across its 52-week range of $6.79 to $41.72, BNR sits at the 11.8% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($9.54 to $12.26).

BNR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

What is BNR's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BNR.

Direct Sub-Reports: BNR RQD Cockpit BNR 12M Forecast BNR Earnings & Move BNR Dividends & DRIP BNR Insiders & 13F BNR Whale Options BNR Profit Sankey BNR News & Why
ROARABLE RATING BRIEF β€’ RQD 20/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

BNR β€” Burning Rock Biotech Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:43:30Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BNR scores 20 out of 100 with a letter grade of E, labeled "Roarable Strong Sell β€” Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 2/20 (ROIC -35%; FCF yield -4.14%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 4/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 0.2; Piotroski F 5/9; Debt/Equity 0.5). The weakest pillar is the cash engine, where negative ROIC and negative free cash flow yield indicate the business is not currently generating returns on invested capital. The forensic balance sheet is the second weakest, with an Altman Z of 0.2, which sits in the distress range of the scale used by the model. For a prospective investor evaluating the stock today, the rating points to elevated downside and balance-sheet risk; upside would depend on a reversal in operating economics that the source data does not yet show. Institutional and insider signals are also weak, so the rating does not rely on a single factor. This is an analytical summary, not personalized advice.

Business

Per the profile, Burning Rock Biotech Limited is a NASDAQ-listed issuer in the Health Care sector, Medical Specialities industry. The source data identifies its market capitalization as $0.1B. Per the recent news wire, the company has an OncoCompass Target CDx Kit that has entered an NMPA priority approval procedure. Not available in source data for the product customers, specific revenue model, or go-to-market structure.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$77.2M$-7.8M$-7.9MN/A$-4.8M$68.4MN/A
FY 2024$70.7M$-49.0M$-47.5MN/A$-13.4M$71.2MN/A
FY 2023$75.7M$-94.3M$-92.1MN/A$-36.0MN/AN/A

Per the market data, gross margin is 74.7%, operating margin is -10.2%, and net margin is -10.3%. ROIC is -35%. Per the RQD pillars, the Altman Z-Score is 0.2 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.5. Reported operating losses narrowed from $-94.3M in FY 2023 to $-7.8M in FY 2025, while cash was $68.4M at the FY 2025 filing. Balance sheet posture, per the source data, is weak on the Altman measure despite the reported cash balance.

Recent Catalysts & News Wire Analysis

  • Positive catalyst: The OncoCompass Target CDx Kit entering NMPA priority approval procedure (per the news wire headline).
  • Coverage flow: Six wire items dated within the last 15 hours reference BNR, all rated YELLOW by the source feed.
  • Insider activity: A headline reports a Burning Rock CEO purchase of 73,141 ADSs for US$618.2K.
  • Risk watch: A headline reports a -1.92% decline on heavy selling on 2026-10-23 (characterized in the source as a stop run); the stock is down -9.87% in the latest session per market data.
  • Proprietary signals: None in the Butterfly graph.

Open Questions

  • What are the reported EPS, debt, and P/E figures, since the source data marks these as N/A or unavailable?
  • Does the FY 2025 cash balance of $68.4M support the company's operating runway at the current $-7.8M operating loss level?
  • What is the revenue mix and customer base behind the $77.2M FY 2025 revenue?
  • What is the timeline and probability for the NMPA priority approval procedure?
  • Who are the 13F institutional holders and insiders behind the cited accumulation and Form 4 activity, given the holder data is NONE?

BNR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Burning Rock Biotech Limited (BNR) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BNR Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BNR Bull vs. Bear Conversation Board β€” What's Your Call at $10.90?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNR 🐻 67% BEARISH CONVICTION
1. Pick Your Side on BNR:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.72 (-12.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is BNR (E β€’ RQD 20/100) a Buy at $11.05?

Welcome to the BNR (Burning Rock Biotech Limited) Roar Pit. Current RQD Composite is 20/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.28 (-16.0%)
Spot @ $11.05

Pump the brakes on BNR β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BNR, but look at what you are paying: current EV/EBITDA multiples with 74.7% gross margins. Unless Burning Rock Biotech Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $13.15 (+19.0%)
Spot @ $11.05

BNR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BNR, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $11.05 (52-wk range $6.79 - $41.72), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%